Drugs / NSC 748933
last change Oct 2019 re-read 2 minutes ago

NSC 748933

Vaccine

Developed for
fallopian tube cancer · ovarian carcinoma · primary peritoneal carcinoma
Investigated by
Gynecologic Oncology Group · National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00857545 Jul 2010 → Sep 2015 fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma Gynecologic Oncology Group Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as NSC 748933 “A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian...” PMID 31653510 Oct 2019
Modality Vaccine “polyvalent vaccineNCT00857545
Route Subcutaneous “Given SC” NCT00857545